Vivek Subbiah: An amazing day at the AACR Industry Roundtable
Vivek Subbiah shared on LinkedIn:
“What an amazing day at the American Association for Cancer Research Industry Roundtable! The agenda for the event was brilliantly conceived with all the key stakeholders in industry.
– The lively and engaging debate on AI on this historic day when AI won Nobel Prize for physics 2024 kept everyone on the edge of their seats.
– A fantastic Oxford-style debate all around conceived by Dr. Lillian Siu and moderated by Dr. Lecia Sequist.
– It was delightful and exciting to participate as an AI enthusiast in the debate with my dear opponent the realist Dr. Alex Pearson.”
More posts featuring Vivek Subbiah on oncodaily.com
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023